Skip to main content

Table 2 Twenty signatures selected for NB-MuSE-classifier construction

From: Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome

Signature* PMID Reference Genes^ Category^^ Features°
Chen 19921788 [22] 50 biology MYCN
De Preter II 16989664 [1] 73 biology Neuroblast transformation
Di Pietro 19402918 [23] 33 biology Apoptosis
Fardin 20624283 [12] 62 biology Tumor hypoxia
Fransson 17044048 [24] 10 biology Chromosome 1p36
Fredlund 18780787 [25] 103 biology MYCN expression
Hahn 18607002 [26] 14 biology Histone deacetylase
McArdle 15090470 [29] 10 biology Chromosome 11q
Nevo II 15081541 [31] 13 biology CXCR4 receptor
Oe 15992370 [28] 117 biology response to NGF
Shimada 17941064 [27] 5 biology Biomarkers
Asgharzadeh 16954472 [20] 44 stratification MYCN non amplified
Benard 19383347 [21] 37 stratification age groups
De Preter I 20179214 [10] 42 stratification Risk/outcome
Fischer 16951229 [8] 17 stratification St4 vs St4s
Nevo II 19739072 [30] 95 stratification St1 vs St4
Oberthuer 17075126 [7] 108 stratification Risk/outcome
Ohira 15837623 [6] 39 stratification Risk/outcome
Vermeulen 19515614 [9] 59 stratification Risk/outcome
Wei 15466177 [4] 12 stratification Risk/outcome
  1. * First author's name of the paper describing the neuroblastoma-related signature used. The signatures predicate patients' outcome with an accuracy > 80%.
  2. ^ Number of genes comprising the signature.
  3. ^^ Categories indicative of the natureof the signature. Biology: the signature discriminates biologically defined situations. Stratification: the signature discriminates classes of tumors derived from patients' stratification.
  4. ° Features: Indications on the nature of the biological questions asked or stratification criteria used. St = INSS stage.